Tag: Patents
Federal Circuit Orders New Trial on LED Tube Lamp Patents After Exclusion of Key Evidence
July 28, 2025
Jiaxing Super Lighting Elec. Appliance, Co., v. CH Lighting Tech. Co Authored by: Jeremy J. Justrowsky In a significant patent dispute over LED tube lamp technology, the Federal Circuit has sent the case of Jiaxing Super Lighting Electric Appliance Co.,…
Read MoreFederal Circuit Clarifies Limits of Interference Estoppel in Patent Reviews: IGT v. Zynga
July 22, 2025
IGT v. Zynga Inc Authored by: Jeremy J. Gustrowsky In a significant decision for patent litigation and the gaming industry, the Federal Circuit affirmed the unpatentability of several claims in IGT’s U.S. Patent No. 7,168,089, which covers secure software transfers…
Read MoreFederal Circuit Clarifies Use of Applicant Admitted Prior Art in Patent Challenges
July 14, 2025
Shockwave Med., Inc. v. Cardiovascular Sys Authored by: Jeremy J. Gustrowsky In the recent case of Shockwave Medical, Inc. v. Cardiovascular Systems, Inc., the Federal Circuit addressed how “Applicant Admitted Prior Art” (AAPA) can be used in patent challenges before…
Read MorePatent Board Denies Rehearing for DeepMind’s Machine Learning Patent Application
July 14, 2025
USPTO Authored by: Jeremy J. Gustrowsky In a recent decision, the Patent Trial and Appeal Board (PTAB) denied a request for rehearing from DeepMind Technologies Limited regarding their U.S. Patent Application No. 16/319,040. The application, which focuses on improving machine…
Read MoreFederal Circuit Upholds Janssen’s Invega Sustenna Patent Against Obviousness Challenge
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a significant decision for pharmaceutical patent holders, the Federal Circuit has affirmed the validity of Janssen Pharmaceuticals’ U.S. Patent No. 9,439,906, which covers specific dosing regimens…
Read MoreFederal Circuit Clarifies Obviousness Standards for Drug Dosing Patents
July 8, 2025
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit provided important guidance on how courts should analyze the obviousness of pharmaceutical dosing regimen patents. The case involved Janssen’s U.S.…
Read MoreFederal Circuit Narrows “Consisting Essentially Of” in Eye Therapies v. Slayback Pharma Patent Dispute
June 30, 2025
Eye Therapies, LLC v. Slayback Pharma, LLC Authored by: Jeremy J. Gustrowsky In a significant decision for patent claim interpretation, the Federal Circuit recently reversed a Patent Trial and Appeal Board (PTAB) ruling in Eye Therapies, LLC v. Slayback Pharma,…
Read MoreFederal Circuit Affirms Dismissal of Mitek’s Declaratory Judgment Suit Against USAA Over Mobile Banking Patents
June 12, 2025
Mitek Sys. v. United Servs. Auto. Ass’n Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit affirmed the dismissal of a declaratory judgment action brought by Mitek Systems, Inc. against United Services Automobile Association (USAA) regarding four…
Read MorePatent Owner’s Silence Not Enough: Federal Circuit Revives Fraunhofer’s Patent Suit Against Sirius XM
June 9, 2025
Fraunhofer-Gesellschaft Zur F_rderung Der Angewandten Forschung E.V. v. Sirius XM Radio Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit reversed a district court’s ruling that had blocked Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung E.V. from…
Read MoreWho Can Appeal a Patent Board Decision? Dolby Labs Learns the Limits
June 5, 2025
Dolby Labs. Licensing Corp. v. Unified Pats., LLC Authored by: Jeremy J. Gustrowsky The Federal Circuit recently dismissed an appeal by Dolby Laboratories Licensing Corporation, clarifying when a party can challenge a Patent Trial and Appeal Board (PTAB) decision in…
Read MorePatent Lexicography Takes Center Stage in Alnylam v. Moderna COVID-19 Vaccine Dispute
June 4, 2025
Alnylam Pharms., Inc. v. Moderna, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit affirmed a district court’s ruling in the high-profile patent dispute between Alnylam Pharmaceuticals, Inc. and Moderna, Inc. over Moderna’s COVID-19 vaccine, SPIKEVAX®.…
Read MoreFederal Circuit Clarifies Patent Claim Scope in X-Ray Imaging Dispute
May 23, 2025
Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit addressed the proper interpretation of patent claims relating to X-ray imaging technology, specifically focusing on U.S. Patent No. 7,400,704, owned…
Read More